These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 2566959)

  • 1. [Medical therapy of peptic ulcer: problems and prospects].
    Trabucchi E; Foschi D; Belloli P; Montorsi F; Marchetti V; Mariscotti C; Diamantini S
    Minerva Dietol Gastroenterol; 1989; 35(1):1-6. PubMed ID: 2566959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptic ulcer in cirrhotic patients: a short- and long-term study with antisecretory drugs.
    Di Mario F; Gottardello L; Germanà B; Dotto P; Grassi SA; Vianello F; Battaglia G; Leandro G; Burra P; Salvagnini M
    Ital J Gastroenterol; 1992; 24(3):122-5. PubMed ID: 1348650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The status of H2-blocker therapy today].
    Rameis H
    Wien Med Wochenschr; 1992; 142(18):398-405. PubMed ID: 1362029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment of peptic ulcers.
    Deveney CW; Deveney KE
    Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [H2 receptor antagonists in the therapy of peptic ulcer disease].
    Dammann HG; Dau B; Dreyer M; Müller P; Simon B
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():136-45. PubMed ID: 2889298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment for gastric and duodenal ulcer.
    Di Mario F; Battaglia G; Pasqualetti P; Vio A; Gottardello L; Grassi SA
    Ital J Gastroenterol; 1990; 22 Suppl 2():24-8. PubMed ID: 1983413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy and prevention of duodenal and gastric ulcer with histamine-H2-receptor antagonists].
    Hentschel E
    Wien Med Wochenschr; 1983; 133(4-5):104-7. PubMed ID: 6134397
    [No Abstract]   [Full Text] [Related]  

  • 8. [Recent developments in drugs antagonistic to factors causing peptic ulcer--clinical effects and problems; histamine H2 receptor blockaders].
    Tani N; Miwa T
    Nihon Rinsho; 1988 Jan; 46(1):12-7. PubMed ID: 2897482
    [No Abstract]   [Full Text] [Related]  

  • 9. Short- and long-term management of peptic ulcer disease: current role of H2-antagonists.
    Brooks WS
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():47-52. PubMed ID: 1349553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of protective drugs in the prevention of ulcer relapse.
    Ota S; Terano A
    J Gastroenterol; 1994 Jul; 29 Suppl 7():139-40. PubMed ID: 7921147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of peptic ulcer maintenance trials.
    Robinson M
    Am J Med; 1984 Nov; 77(5B):23-9. PubMed ID: 6095657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term treatment of peptic ulcer with histamine H2 receptor blockaders: results of their use and new problems].
    Grigor'ev PIa; Isakov VA
    Klin Med (Mosk); 1991 Oct; 69(10):93-7. PubMed ID: 1685004
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent advances in the treatment of digestive diseases.
    Sun HS
    J Int Med Res; 1989; 17 Suppl 1():2A-8A. PubMed ID: 2566540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
    Thomson AB; Mahachai V
    Clin Invest Med; 1987 May; 10(3):152-70. PubMed ID: 2887321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists.
    Chelvam P; Wong EC
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():75-81. PubMed ID: 2577478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].
    Simon B; Müller P; Dammann HG
    Wien Med Wochenschr; 1982 May; 132(10):223-8. PubMed ID: 6126962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.
    Freston JW
    Am J Gastroenterol; 1987 Dec; 82(12):1242-9. PubMed ID: 2891294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H2-blockers: how safe and how effective?
    Spiro HM
    J Clin Gastroenterol; 1983; 5 Suppl 1():143-7. PubMed ID: 6140282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug therapy of peptic ulcer disease.
    Ching CK; Lam SK
    Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical importance of the new H2-antagonists.
    Walt RP
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():97-9. PubMed ID: 2566730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.